| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/19/2001 | CA2397741A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 07/19/2001 | CA2397707A1 Compositions for enhancing the immune response |
| 07/19/2001 | CA2397575A1 Antibacterial agents |
| 07/19/2001 | CA2397386A1 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 07/19/2001 | CA2397374A1 Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| 07/19/2001 | CA2397345A1 Arylsulfonic acid salts of pyrimidine-based antiviral agents |
| 07/19/2001 | CA2397340A1 Drug metabolizing enzymes |
| 07/19/2001 | CA2397283A1 New imidazole derivatives |
| 07/19/2001 | CA2397207A1 Novel stra6 polypeptides |
| 07/19/2001 | CA2397092A1 Processes for preparing clarithromycin polymorphs |
| 07/19/2001 | CA2397081A1 Novel vitamin d analogues |
| 07/19/2001 | CA2397068A1 Pharmaceutical and cosmetic carrier or composition for topical application |
| 07/19/2001 | CA2396966A1 Methods for synthesis of .alpha.-d-gal (1.fwdarw.3) gal-containing oligosaccharides |
| 07/19/2001 | CA2396962A1 Benzosulfones and related compositions and methods |
| 07/19/2001 | CA2396950A1 Racemic and optically pure metabolites of sibutramine, their preparation, compositions comprising them and their use as dopamine reuptake inhibitors |
| 07/19/2001 | CA2396915A1 Sodium ion absorption inhibitors, and preventive and therapeutic agents and foods containing the same |
| 07/19/2001 | CA2396560A1 Tricyclic compounds and method of treating herpes virus |
| 07/19/2001 | CA2396413A1 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof |
| 07/19/2001 | CA2396368A1 Use of a composition comprising two quaternary ammonium compounds and an organometallic compound for treating viral and fungal infections and diseases |
| 07/19/2001 | CA2396214A1 Osmotic device containing alprazolam and an antipsychotic agent |
| 07/19/2001 | CA2396199A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors |
| 07/19/2001 | CA2396157A1 Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
| 07/19/2001 | CA2396120A1 Treatment of diabetic ulcers |
| 07/19/2001 | CA2396098A1 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 07/19/2001 | CA2396087A1 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 07/19/2001 | CA2396071A1 Thickened oil compositions of edible oil |
| 07/19/2001 | CA2396044A1 Improved topical drug delivery composition and method |
| 07/19/2001 | CA2396026A1 Phenanthridine-n-oxides |
| 07/19/2001 | CA2396007A1 Piperidine and piperazine derivatives |
| 07/19/2001 | CA2395975A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/19/2001 | CA2394833A1 Derivatives of polyene macrolides and preparation and use thereof |
| 07/19/2001 | CA2393597A1 Indole derivatives as mcp-1 receptor antagonists |
| 07/19/2001 | CA2393592A1 Indole derivatives as mcp-1 receptor antagonists |
| 07/19/2001 | CA2392731A1 Prevention and treatment of endotoxemia and related complications associated with surgery |
| 07/19/2001 | CA2383158A1 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance |
| 07/19/2001 | CA2366621A1 Use of epigallocatechin-gallate for inhibiting angiogenesis |
| 07/19/2001 | CA2366599A1 Treatment of hepatitis c using hyperthermia |
| 07/19/2001 | CA2366411A1 Topical medicated bioadhesive compositions and methods of use and preparation thereof |
| 07/18/2001 | EP1116716A1 Piperidine and piperazine compounds for use in the treatment of Alzheimer |
| 07/18/2001 | EP1116488A2 Treatment of inflammatory Bowel disease |
| 07/18/2001 | EP1116487A2 Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| 07/18/2001 | EP1116486A1 Medical composition containing nitroetheneamine derivative or salt thereof as active constituent |
| 07/18/2001 | EP1116485A2 Instant granulate and process for its preparation |
| 07/18/2001 | EP1116484A2 Treatment of a cosmetic with NIR-rays and its use |
| 07/18/2001 | EP1116027A1 Identifying agents that alter mitochondrial permeability transition pores |
| 07/18/2001 | EP1115877A1 Polynucleotide constructs and uses thereof |
| 07/18/2001 | EP1115871A2 Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug |
| 07/18/2001 | EP1115859A2 Hairpin hybridizer molecules for modulation of gene expression |
| 07/18/2001 | EP1115849A2 Genes of the 1-desoxy-d-xylulose biosynthetic pathway |
| 07/18/2001 | EP1115747A1 Polymer complexes of glucuronoglucanes |
| 07/18/2001 | EP1115733A1 Sequences characteristic of hypoxia-regulated gene transcription |
| 07/18/2001 | EP1115729A1 Phosphonic acid derivatives as inhibitors of ptp-1b |
| 07/18/2001 | EP1115725A1 Tetrahydropyridoethers |
| 07/18/2001 | EP1115721A1 Pyrimidone derivatives |
| 07/18/2001 | EP1115720A2 Novel n-(iminomethyl)amine derivatives, their preparation, their use as medicines and compositions containing them |
| 07/18/2001 | EP1115719A2 Novel amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same |
| 07/18/2001 | EP1115718A1 Hydroxyflavone derivatives as tau protein kinase 1 inhibitors |
| 07/18/2001 | EP1115716A1 2-phenylpyran-4-one derivatives |
| 07/18/2001 | EP1115712A1 Oxazole compounds as prostaglandin e2 agonists or antagonists |
| 07/18/2001 | EP1115708A1 Aminoalkyl-3,4-dihydroquinoline derivates as no-synthase inhibitors |
| 07/18/2001 | EP1115707A1 Benzamide derivatives and ther use as cytokine inhibitors |
| 07/18/2001 | EP1115704A1 Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes |
| 07/18/2001 | EP1115703A1 Cyclic ester or amide derivatives |
| 07/18/2001 | EP1115702A1 Substituted nitrogen and sulfur alicyclic compounds, including methods for synthesis thereof |
| 07/18/2001 | EP1115701A1 Arylsulfonanilide ureas |
| 07/18/2001 | EP1115697A1 Unsaturated hydroximic acid derivatives as parp inhibitors |
| 07/18/2001 | EP1115695A1 (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| 07/18/2001 | EP1115694A1 Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
| 07/18/2001 | EP1115693A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY |
| 07/18/2001 | EP1115687A1 5,6-dihydronaphthalenyl derivatives having retinoid-like activity |
| 07/18/2001 | EP1115478A2 Emollient esters based upon capryl alcohol and isostearic acid |
| 07/18/2001 | EP1115422A1 Use of non-peptidyl compounds for the treatment of insulin related ailments |
| 07/18/2001 | EP1115420A2 Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine |
| 07/18/2001 | EP1115419A2 Carbapenem antibacterial compositions and methods of treatment |
| 07/18/2001 | EP1115418A2 Aglyco products and methods of use |
| 07/18/2001 | EP1115417A2 Methods for administration of antibiotics |
| 07/18/2001 | EP1115416A1 Use of substances with oxytocin activity in order to create cell regeneration |
| 07/18/2001 | EP1115412A1 Neuroimmunophilins for selective neuronal radioprotection |
| 07/18/2001 | EP1115409A1 Composition for extending post meal satiety |
| 07/18/2001 | EP1115406A2 Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
| 07/18/2001 | EP1115405A1 Use of certain drugs for treating nerve root injury |
| 07/18/2001 | EP1115404A1 Use of prostanoid antagonists for the treatment of primary headache disorders |
| 07/18/2001 | EP1115403A1 Optimized use of 6-mercaptopurine drug in the treatment of immune-mediated gastrointestinal disorders |
| 07/18/2001 | EP1115402A1 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
| 07/18/2001 | EP1115399A1 Use of a pharmaceutical composition containing, in combination, an antagonist of the angiotensin ii at 1? receptors and indomethacin for making a medicine treating chronic glomerulonephritis |
| 07/18/2001 | EP1115398A1 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| 07/18/2001 | EP1115397A1 Method of mitigating the adverse effects of interleukin-2 |
| 07/18/2001 | EP1115396A1 Pharmaceutically active compounds and methods of use thereof |
| 07/18/2001 | EP1115395A1 ACTIVE ENANTIOMER OF RARgamma-SPECIFIC AGONIST |
| 07/18/2001 | EP1115394A2 Pharmaceutical compositions comprising derivatives of sulphur acids |
| 07/18/2001 | EP1115393A1 Sulfonamide derivatives |
| 07/18/2001 | EP1115392A2 Use of n-acylvanillinamide derivatives as agonists of peripheral cannabinoid cb1 receptors |
| 07/18/2001 | EP1115391A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| 07/18/2001 | EP1115390A1 Hydroxamate-containing cysteine and serine protease inhibitors |
| 07/18/2001 | EP1115389A1 Fructosamine oxidase: antagonists and inhibitors |
| 07/18/2001 | EP1115388A1 Use of organophosphorous compounds for producing medicaments for the therapeutic and prophylactic treatment of infections or as a fungicide, bactericide or herbicide for plants |
| 07/18/2001 | EP1115387A2 Anti-microbial-adhesion fraction derived from vaccinium |
| 07/18/2001 | EP1115386A2 Treatment of infection |
| 07/18/2001 | EP1115384A1 Fentanyl composition for the treatment of acute pain |
| 07/18/2001 | EP1115383A1 Pharmaceutical composition for the treatment of acute disorders |